Home Performance of different screening methods for the determination of urinary glycosaminoclycans
Article
Licensed
Unlicensed Requires Authentication

Performance of different screening methods for the determination of urinary glycosaminoclycans

  • Ebru Afyoncu , Gülsen Yılmaz , Fatma M. Yılmaz and Doğan Yücel EMAIL logo
Published/Copyright: September 15, 2012

Abstract

Background: The study aim was to compare the performance of three different methods used for determining urinary glycosaminoglycans (GAG) levels in spot and 24-h urine samples.

Methods: Performance characteristics were studied for cetylpyridinium chloride (CPC), and manual and automated dimethylmethylene blue (DMB) methods.

Results: For automated DMB method, within-run precisions were 9.10% and 1.98%, and between-day precisions were 13.0% and 5.81% in low- and high-urine pools, respectively. The method was linear up to 100 mg/L of GAG concentration. The detection limit of the method was 0.71 mg/L. Mean recovery was 95.7%.

Conclusions: The automated DMB method was found to give better performance characteristics than cetylpyridinium chloride (CPC) and manual DMB methods. It is a fast, cheap, simple and reliable method and can be applied in many diseases in which GAG is used as a screening test.


Corresponding author: Doğan Yücel, S.B. Ankara Eğitim ve Araştırma Hastanesi, Tıbbi Biyokimya Bölümü, Cebeci/Ankara, Turkey, Fax: +90 312 3621857

References

1. Andrade F, Prieto JA, Elorz J, Martín S, Sanjurjo P, Aldámiz-Echevarría L. Stability of urinary glycosaminoglycans in patients with mucopolysaccharidoses. Clin Chim Acta 2008;388:73–7.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000252770800012&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1016/j.cca.2007.10.007Search in Google Scholar

2. Mabe P, Valiente A, Soto V, Cornejo V, Raimann E. Evaluation of reliability for urine mucopolysaccharidosis screening by dimethylmethylene blue and Berry spot tests. Clin Chim Acta 2004;345:135–40.10.1016/j.cccn.2004.03.015Search in Google Scholar

3. Whitley CB, Ridnour MD, Draper KA, Dutton CM, Neglia JP. Diagnostic test for mucopolysaccharidosis: I. Direct method for quantifying excessive urinary glycosaminoglycan excretion. Clin Chem 1989;35:374–9.10.1093/clinchem/35.3.374Search in Google Scholar PubMed

4. de Jong JG, Wevers RA, Laarakkers C, Poorthuis BJ. Dimethylmethylene blue-based spectrophotometry of glycosaminoglycans in untreated urine: a rapid screening procedure for mucopolysaccharidosis. Clin Chem 1989;35:1472–7.10.1093/clinchem/35.7.1472Search in Google Scholar

5. Pennock CA. A review and selection of simple laboratory methods used for the study of glycosaminoglycan excretion and the diagnosis of the mucopolysaccharidoses. J Clin Path 1976;29:111–23.10.1136/jcp.29.2.111Search in Google Scholar

6. Kéry V, Orlovska M, Stancikova M, Risko M, Zlnay D. Urinary glycosaminoglycan excretion in rheumatic diseases. Clin Chem 1992;38:841–6.10.1093/clinchem/38.6.841Search in Google Scholar PubMed

7. Clinical and Laboratory Standards Institute. Method comparison and bias estimation using patient samples; approved guideline. CLSI Document EP9-A2, 2nd ed. Wayne (PA): CLSI, 2002.Search in Google Scholar

8. Farndale RW, Buttle DJ, Barrett AJ. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta 1986;883:173–7.10.1016/0304-4165(86)90306-5Search in Google Scholar

9. Whitley CB, Spielmann RC, Herro G, Teragawa SS. Urinary glycosaminoglycan excretion quantified by an automated semimicro method in specimens conveniently transported from around the globe. Mol Genet Metab 2002;75:56–64.10.1006/mgme.2001.3271Search in Google Scholar PubMed

10. Elmen W, Niebur J, Flanders G, Rutledge J. Measurement of serum hyaluronic acid in patients with rheumatoid arthritis: correlation with disease activity. J Rheumatol 1996;23:6.Search in Google Scholar

11. Goldberg JM, Cotlier E. Specific isolation and analysis of mucopolysaccharides (glycosaminoglycans) from human urine. Clin Chim Acta 1972;41:19–27.10.1016/0009-8981(72)90491-3Search in Google Scholar PubMed

12. Alonso-Fernández JR, Fidalgo J, Colón C. Neonatal screening for mucopolysaccharidoses by determination of glycosaminoglycans in the eluate of urine-impregnated paper: preliminary results of an improved DMB-based procedure. J Clin Lab Anal 2010;24:149–53.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000278032500005&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1002/jcla.20375Search in Google Scholar PubMed PubMed Central

Received: 2012-07-21
Accepted: 2012-08-20
Published Online: 2012-09-15
Published in Print: 2013-02-01

©2013 by Walter de Gruyter Berlin Boston

Articles in the same Issue

  1. Letters to the Editor
  2. Performance evaluation of three different immunoassays for detection of antibodies to hepatitis B core
  3. Serum homocysteine concentrations in Chinese children with autism
  4. Interchangeability of venous and capillary HbA1c results is affected by oxidative stress
  5. Interference of hemoglobin (Hb) N-Baltimore on measurement of HbA1c using the HA-8160 HPLC method
  6. First human isolate of Mycobacterium madagascariense in the sputum of a patient with tracheobronchitis
  7. Protein S and protein C measurements should not be undertaken during vitamin K antagonist therapy
  8. α2-HS glycoprotein is an essential component of cryoglobulin associated with chronic hepatitis C
  9. An unusual interference in CK MB assay caused by a macro enzyme creatine phosphokinase (CK) type 2 in HIV-infected patients
  10. An automated technique for the measurement of the plasma glutathione reductase activity and determination of reference limits for a healthy population
  11. Is osteopontin stable in plasma and serum?
  12. Evidence-based approach to reducing perceived wasteful practices in laboratory medicine
  13. Masthead
  14. Masthead
  15. Editorials
  16. Testing volume is not synonymous of cost, value and efficacy in laboratory diagnostics
  17. Lessons from controversy: biomarkers evaluation
  18. Commercial immunoassays in biomarkers studies: researchers beware!1)
  19. Trials and tribulations in lupus anticoagulant testing
  20. Reviews
  21. Mass spectrometry: a revolution in clinical microbiology?
  22. Chronic Chagas disease: from basics to laboratory medicine
  23. General Clinical Chemistry and Laboratory Medicine
  24. Shop for quality or quantity? Volumes and costs in clinical laboratories
  25. Minor improvement of venous blood specimen collection practices in primary health care after a large-scale educational intervention
  26. Evaluation of high resolution gel β2-transferrin for detection of cerebrospinal fluid leak
  27. Serum kallikrein-8 correlates with skin activity, but not psoriatic arthritis, in patients with psoriatic disease
  28. Soluble urokinase plasminogen activator receptor (suPAR) in the assessment of inflammatory activity of rheumatoid arthritis patients in remission
  29. Bone mass density selectively correlates with serum markers of oxidative damage in post-menopausal women
  30. Validation of a fast and reliable liquid chromatography-tandem mass spectrometry (LC-MS/MS) with atmospheric pressure chemical ionization method for simultaneous quantitation of voriconazole, itraconazole and its active metabolite hydroxyitraconazole in human plasma
  31. Performance of different screening methods for the determination of urinary glycosaminoclycans
  32. Intestinal permeability and fecal eosinophil-derived neurotoxin are the best diagnosis tools for digestive non-IgE-mediated cow’s milk allergy in toddlers
  33. An internal validation approach and quality control on hematopoietic chimerism testing after allogeneic hematopoietic cell transplantation
  34. Serum levels of IgG antibodies against oxidized LDL and atherogenic indices in HIV-1-infected patients treated with protease inhibitors
  35. Cooperation experience in a multicentre study to define the upper limits in a normal population for the diagnostic assessment of the functional lupus anticoagulant assays
  36. Contribution of procoagulant phospholipids, thrombomodulin activity and thrombin generation assays as prognostic factors in intensive care patients with septic and non-septic organ failure
  37. Suitability of POC lactate methods for fetal and perinatal lactate testing: considerations for accuracy, specificity and decision making criteria
  38. Point-of-care testing on admission to the intensive care unit: lactate and glucose independently predict mortality
  39. Reference Values and Biological Variations
  40. CA125 reference values change in male and postmenopausal female subjects
  41. Distributions and ranges of values of blood and urinary biomarker of inflammation and oxidative stress in the workers engaged in office machine manufactures: evaluation of reference values
  42. Cancer Diagnostics
  43. Association of acute phase protein-haptoglobin, and epithelial-mesenchymal transition in buccal cancer: a preliminary report
  44. Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients
  45. Evaluation of the BRAHMS Kryptor® Thyroglobulin Minirecovery Test in patients with differentiated thyroid carcinoma
Downloaded on 16.11.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2012-0471/html?lang=en
Scroll to top button